Search Results for "Grifols Biologicals Email"
Original Source: Grifols, Inc.
Currently, we supply plasma products, diagnostic reagents, automated analyzers and dosing machines.In 1998, Grifols established a joint venture with a US diagnostic company, Quest International. Then, in 2000 in order to prepare for an even greater presence in the USA with its plasma products, Grifols founded Grifols USA.Grifols acquired SeraCare’s network of 45 plasmapheresis centers in 2002, thereby vertically integrating the company and guaranteeing its supply of plasma. A year later, Grifols acquired...
Matching Channels
Hepatitis B Immune Globulin Grifols
Tetanus Immune Globulin Grifols
BioPortfolio has launched a number of Facebook pages to allow our visitors to keep track with latest news, published paper and clinical trials by lead biotechnology and healthcare topics:- &nbs...
Matching News
Annual Report for 2012 on Form 20-F filed with the SEC on April 5, 2013
BARCELONA, Spain, April 5, 2013 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE:GRF, MCE:GRF.P and NASDAQ: GRFS), announced that it has filed its 2012 Annual Report on Form 20-F with the United States...
Return to top 50 pharma list Summary Website: Grifols Headquarters: Barcelona, Spain Ticker Symbol: GRF:Continuous SEC Link: Grifols SEC filings Subsidiaries: Araclon Biotech PlasmaCare Talecris B...
[Grifols] acquires 60% of [Progenika] for €37mm
[Grifols SA] (hemotherapy, diagnostics, and hospital IV drugs) is acquiring a 60% stake in privately held diagnostics company [Progenika Biopharma SA] for €37mm ($48mm), half of which was paid in ca...
Russia to harmonize biologicals regulations
International regulatory bodies and the drug industry met in Moscow on 15 May 2013 to discuss how to harmonize Russia’s regulatory standards for biologicals with the rest of the world to develop a f...
Grifols big pharma deals Aradigm in licensing and option agreement for Pulmaquin, Lipoquin and AERx
Grifols, a big pharma company, has entered pharma deals with Aradigm for licensing and options relating to Pulmaquin, Lipoquin and AERx. Grifols and Aradigm announced the signing of pharma deals...
Spain's Grifols says Q1 net profit up 19 pct y/y
MADRID, May 2 (Reuters) - Spanish pharmaceutical company Grifols said on Thursday net profit rose 19 percent in the first quarter of 2013 from a year earlier to 115.7 million euros ($152.6 million), b...
Grifols signs $90.7m respiratory deal with Aradigm
Grifols has signed a worldwide licensing agreement worth up to $90.7m to develop and commercialize Aradigm's formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe...
Grifols acquires 40% of Spanish biotech firm VCN Bioscience
Spanish health care group Grifols (GRLS: MC), the world's third largest plasma product manufacturer, has acquired 40% of the equity of Catalan biotechnology firm VCN Biosciences, dedicated to the R&D...
Matching PubMed Articles
The importance of biologicals in the treatment of SoJIA.
Systemic onset juvenile idiopathic arthritis (SoJIA) remains difficult to treat. In addition to conventional antirheumatic therapy with non-steroidal antirheumatic drugs (NSARDs), steroids or disease-...
What are the factors influencing the trustworthiness of data produced in email interviews? The main purpose of this article is to reflect on this issue by discussing two examples from my own experienc...
The variant Creutfeldt-Jakob disease (vCJD) is a transmissible spongiform encephalopathy (TSE) associated with the ingestion of cattle derived products affected with bovine spongiform encephalopathy....
Therapy with biologicals for the management of rheumatic diseases has improved treatment options and dramatically increased expectations of patients and doctors. Remission is a reasonable therapeutic...
PURPOSE: To describe the global effort targeting the major causes of mortality in terms of "open" early phase clinical trials with drugs and biologicals. METHODS: Sixteen of the 20 leading causes of d...
